MML Investors Services LLC Has $1.79 Million Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

MML Investors Services LLC increased its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 3.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,361 shares of the medical research company’s stock after purchasing an additional 159 shares during the quarter. MML Investors Services LLC’s holdings in Bio-Rad Laboratories were worth $1,794,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Avior Wealth Management LLC lifted its holdings in shares of Bio-Rad Laboratories by 3.3% during the 3rd quarter. Avior Wealth Management LLC now owns 999 shares of the medical research company’s stock worth $334,000 after acquiring an additional 32 shares during the period. UMB Bank n.a. lifted its stake in Bio-Rad Laboratories by 140.6% during the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock worth $26,000 after purchasing an additional 45 shares during the last quarter. Capital Advisors Ltd. LLC raised its holdings in shares of Bio-Rad Laboratories by 193.8% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock worth $26,000 after buying an additional 62 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Bio-Rad Laboratories by 9.5% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 947 shares of the medical research company’s stock valued at $259,000 after buying an additional 82 shares in the last quarter. Finally, Quarry LP increased its position in Bio-Rad Laboratories by 38.1% during the 3rd quarter. Quarry LP now owns 297 shares of the medical research company’s stock worth $99,000 after purchasing an additional 82 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Bio-Rad Laboratories Stock Down 1.7 %

Shares of NYSE:BIO opened at $337.28 on Wednesday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14. Bio-Rad Laboratories, Inc. has a 52-week low of $262.12 and a 52-week high of $387.99. The business’s 50 day simple moving average is $341.35 and its two-hundred day simple moving average is $322.07. The firm has a market cap of $9.44 billion, a P/E ratio of -12.34 and a beta of 0.90.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The firm had revenue of $649.70 million for the quarter, compared to the consensus estimate of $628.18 million. During the same quarter in the prior year, the company posted $2.33 earnings per share. The business’s revenue was up 2.8% on a year-over-year basis. As a group, research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.29 EPS for the current fiscal year.

Analyst Ratings Changes

BIO has been the topic of several recent research reports. Citigroup raised their price objective on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Wells Fargo & Company assumed coverage on shares of Bio-Rad Laboratories in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price target for the company. StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Finally, Royal Bank of Canada raised their price objective on Bio-Rad Laboratories from $369.00 to $481.00 and gave the stock an “outperform” rating in a research report on Monday, December 9th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $394.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.